Published

07 Dec 25

Updated

26 Jun 26

Views

251

Not Invested

PrecigenPGEN

Fair Value

US$12.45

Share price26 Jun

US$5.456.6% undervalued

1Y243.95%

7D9.09%

Gene And Immunotherapy Expansion Will Drive Durable Long Term Opportunity

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

07 Dec 25

Updated

26 Jun 26

Views

251

Not Invested

Shared on 26 Jun 26

Fair value Increased 46%

PGEN: Orphan Exclusivity And Durable RRP Data Will Drive Future Upside

Precigen’s PAPZIMEOS gets a stronger backdrop as regulators grant a period where similar rival treatments can’t easily enter, and longer-term follow-up suggests many patients keep benefiting for years without new safety surprises. Analysts respond by lifting their view of what the business could be worth, while still flagging that future results need to keep matching the early launch momentum.

62 views

Fair Value vs Share Price

US$12.45

vs US$5.456.6% undervalued

148.1%

Revenue growth

65.8%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Precigen

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

High growth potential with low risk.

Market capUS$1.9b

PB95.1x

Estimated Growth42.4%

Dividend YieldN/A

Full analysis

CEO & management

Helen Sabzevari

CEO

6.5yrs

CEO Tenure

A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.